What to Expect From Insulet's Next Quarterly Earnings Report

Core Viewpoint - Insulet Corporation (PODD) is an innovative medical device company focused on insulin delivery systems, with a market cap of $22.8 billion, and is set to announce its fiscal third-quarter earnings for 2025 on November 6 [1] Financial Performance - Analysts expect PODD to report a profit of $1.13 per share for the upcoming quarter, reflecting a 25.6% increase from $0.90 per share in the same quarter last year [2] - For the full fiscal year, EPS is projected to be $4.61, a 42.3% increase from $3.24 in fiscal 2024, with further growth expected to $5.76 in fiscal 2026, representing a 25% year-over-year rise [3] Stock Performance - PODD stock has outperformed the S&P 500 Index, which gained 16.2% over the past 52 weeks, with PODD shares increasing by 37.7% during the same period [4] - The stock also outperformed the Health Care Select Sector SPDR Fund, which saw a 2.9% decline [4] Growth Drivers - The strong performance of PODD is attributed to significant growth in its Omnipod product line in both domestic and international markets [5] - Following the release of Q2 results, PODD shares surged 9.5% after reporting an adjusted EPS of $1.17, exceeding expectations of $0.93, with revenue reaching $649.1 million, surpassing forecasts of $615.5 million [5] Analyst Sentiment - The consensus among analysts is bullish, with a "Strong Buy" rating for PODD stock; 21 out of 25 analysts recommend a "Strong Buy," while two suggest a "Moderate Buy" and two a "Hold" [6] - The average analyst price target for PODD is $365.78, indicating a potential upside of 13.1% from current levels [6]